GP404141 + Nplate
Phase 3Active 1 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Drug Effect
Conditions
Drug Effect, Safety Issues, Immunogenicity
Trial Timeline
Apr 4, 2023 → Mar 31, 2028
NCT ID
NCT06497036About GP404141 + Nplate
GP404141 + Nplate is a phase 3 stage product being developed by GEROPHARM for Drug Effect. The current trial status is active. This product is registered under clinical trial identifier NCT06497036. Target conditions include Drug Effect, Safety Issues, Immunogenicity.
What happened to similar drugs?
8 of 14 similar drugs in Drug Effect were approved
Approved (8) Terminated (3) Active (4)
✅Polyene phosphatidylcholine injection 930 mg QD + Magnesium Isoglycyrrhizinate injection 200 mg QDHaisco Pharmaceutical GroupApproved
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06497036 | Phase 3 | Active |
Competing Products
20 competing products in Drug Effect